These innovative agents represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://rafaelropg646937.loginblogin.com/47132989/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide